Jacob Johnson
Stock Analyst at Stephens & Co.
(4.01)
# 602
Out of 4,711 analysts
80
Total ratings
46.15%
Success rate
14.17%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Upgrades: Overweight | $50 → $60 | $50.43 | +18.98% | 5 | Dec 18, 2024 | |
| STE STERIS | Reiterates: Overweight | $260 | $207.49 | +25.31% | 6 | Nov 7, 2024 | |
| DHR Danaher | Reiterates: Overweight | $315 | $228.55 | +37.83% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher | Initiates: Overweight | $680 | $524.05 | +29.76% | 1 | Oct 1, 2024 | |
| CDMO Avid Bioservices | Reiterates: Overweight | $12 | $12.30 | -2.44% | 7 | Sep 10, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $144.46 | +17.68% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $7.73 | -35.32% | 5 | Jul 10, 2024 | |
| MASS 908 Devices | Reiterates: Overweight | $14 | $2.06 | +579.61% | 3 | May 13, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $4.24 | +159.43% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $20.56 | +84.82% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $7.86 | +116.28% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.58 | +58.23% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $73.17 | +18.90% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $331.40 | +17.68% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $9 | $7.24 | +24.31% | 3 | Sep 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $16.41 | +9.69% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $5.28 | +13.64% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $27.39 | +5.88% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $114.64 | +13.40% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $185.77 | +102.94% | 1 | Apr 7, 2022 |
Azenta
Dec 18, 2024
Upgrades: Overweight
Price Target: $50 → $60
Current: $50.43
Upside: +18.98%
STERIS
Nov 7, 2024
Reiterates: Overweight
Price Target: $260
Current: $207.49
Upside: +25.31%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $228.55
Upside: +37.83%
Thermo Fisher
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $524.05
Upside: +29.76%
Avid Bioservices
Sep 10, 2024
Reiterates: Overweight
Price Target: $12
Current: $12.30
Upside: -2.44%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $144.46
Upside: +17.68%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $7.73
Upside: -35.32%
908 Devices
May 13, 2024
Reiterates: Overweight
Price Target: $14
Current: $2.06
Upside: +579.61%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $4.24
Upside: +159.43%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $20.56
Upside: +84.82%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $7.86
Upside: +116.28%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.58
Upside: +58.23%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $73.17
Upside: +18.90%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $331.40
Upside: +17.68%
Sep 1, 2023
Maintains: Equal-Weight
Price Target: $8 → $9
Current: $7.24
Upside: +24.31%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $16.41
Upside: +9.69%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $5.28
Upside: +13.64%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $27.39
Upside: +5.88%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $114.64
Upside: +13.40%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $185.77
Upside: +102.94%